Mycophenolate Mofetil Morningside Healthcare (Mycophenolate Mofetil)

After oral administration, mycophenolate mofetil is converted to mycophenolic acid, which blocks inosine monophosphate dehydrogenase. This inhibition stops the synthesis of guanosine nucleotides needed for T‑ and B‑cell proliferation, thereby suppressing the immune response.

The appropriate dose of Mycophenolate Mofetil is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and concomitant therapies. Patients should follow the dosage instructions provided by their healthcare professional.

Mycophenolate Mofetil is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. It is also not recommended while breastfeeding because it can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine, mycophenolate mofetil offers a different mechanism—targeting nucleotide synthesis rather than calcineurin signaling. It is often used in combination regimens to achieve synergistic immunosuppression while potentially reducing the dose‑related toxicities of each agent.

The product should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. No refrigeration is required for the oral formulation.

Mycophenolate Mofetil is taken orally, usually with food or a glass of water to improve tolerability. The exact schedule—once or twice daily—depends on the prescribing clinician’s regimen.

Serious risks include profound leukopenia, severe infections, hepatic toxicity, and an increased long‑term risk of certain malignancies. Patients should be monitored regularly for blood count changes, liver function abnormalities and signs of infection.

Mycophenolate Mofetil should not be used by individuals who are pregnant, breastfeeding, have known hypersensitivity to the drug, or have uncontrolled infections. It is also contraindicated in patients with severe renal impairment unless dose adjustments are made by a specialist.